Please login to the form below

Not currently logged in
Email:
Password:

licence deal

This page shows the latest licence deal news and features for those working in and with pharma, biotech and healthcare.

CymaBay Therapeutics plummets after abandoning NASH drug

CymaBay Therapeutics plummets after abandoning NASH drug

German drugmaker Boehringer is also looking to enter the market, after it signed a $870m licence deal with South Korean biotech Yuhan in  July  to bolster its NASH pipeline. ... The deal will draw on Yuhan’s expertise in fibroblast growth fact 21

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... The deal also includes a licence to

  • Deal Watch October 2016 Deal Watch October 2016

    Astellas has structured its deal almost like a licence with one third of the consideration ($462m) upfront and the remainder in “further contingent milestones” (milestones and possibly royalties) as the product ... The licence deal obtained by Summit

  • Deal Watch May 2016 Deal Watch May 2016

    Building on its 2014 deal with MacroGenics, J&J entered into a licence and collaboration agreement for MGD015 for B-cell malignancies with an upfront fee of $75m and $665m in ... Another deal which has taken a hybrid licence / acquisition format is that

  • Deal Watch January 2016 Deal Watch January 2016

    The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected peak sales in the range of $0.6bn to $1.0bn (the first nine ... Licensor/Acquired Acquiror/Partner. Deal Type. Comments. Hline $m. Baxalta/

  • Pharma deals in July 2015 Pharma deals in July 2015

    Biogen also broke the $1bn headline in a licence and collaboration deal with AGTC for gene based therapies to treat ophthalmic diseases. ... A strange coincidence! Licensor/Licensee Acquired / Acquirer. Deal type. Product/Technology. Headline $m.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics